January 3, 2007 – Amgen struck a $725 million deal with Cytokinetics to develop heart failure drugs based on cardiac myosin; Genentech optioned an Exelixis cancer drug candidate; VaxGen sold its share in Celltrion for $51.3 million; Theravance began treating patients in a Phase II trial of a new antibiotic; Medtronic published positive data on a device for Meniere’s disease; CoGenesys is seeking permission to start human testing of an antibiotic in patients taking myelosuppressive anti-cancer drugs; and Amylin and Lilly received FDA approval to market Byetta as an add-on to thiazolidinedione (TZD). The Centient Biotech 200™ was down 4 points at 3919, a loss of .10%. More details...
